Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.50 |
| ▸ | HTR2C | P28335 | 16/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344999 | 0.77 | MAPT (0.38) | MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL3562423 | 0.69 | ADH1A (0.38) | MAPTALDH1A1HPGD | |
| SCHEMBL3567525 | 0.68 | ADH1A (0.37) | MAPTALDH1A1HPGDNPC1 | |
| SCHEMBL3453651 | 0.67 | MAPT (0.46) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL9419059 | 0.64 | NPC1 (0.55) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL29793289 | 0.62 | NPC1 (0.67) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL21584068 | 0.62 | NPC1 (0.67) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL12778355 | 0.62 | NPC1 (0.51) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL50671 | 0.62 | ALDH1A1 (0.82) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL30301801 | 0.62 | ALDH1A1 (0.82) | MAPTALDH1A1HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | MTNR1A 253/4885MTNR1B 371/4885HTR2C 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.